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The success of a primary percutaneous intervention (PCI) in the setting of ST elevation myocardial infarction depends on the functional and
structural integrity of coronary microcirculation. Coronary microvascular dysfunction and obstruction (CMVO) occurs in up to half of patients
submitted to apparently successful primary PCI and is associated to a much worse outcome. The current review summarizes the complex
mechanisms responsible for CMVO, including pre-existing coronary microvascular dysfunction, and highlights the current limitations in the
assessment of microvascular function. More importantly, at the light of the substantial failure of trials hitherto published on the treatment
of CMVO, this review proposes a novel integrated therapeutic approach, which should overcome the limitations of previous studies.
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Introduction
ST-segment elevation myocardial infarction (STEMI) usually results
from acute thrombotic occlusion of a coronary artery and is a lead-
ing cause of death.1 The goal of reperfusion therapy with fibrinolytic
drugs or primary percutaneous coronary intervention (PCI) is to re-
store blood flow to ischaemic, but still viable, myocardium, and re-
duce infarct size (IS). Accordingly, reducing time to treatment and
maximizing myocardial salvage—in keeping with the mantra that
‘time is muscle’—represents a major challenge in the management
of STEMI.2 However, although national door-to-balloon times
have improved significantly over the last years for patients undergo-
ing primary PCI, in-hospital mortality has remained virtually un-
changed.3,4 Additional strategies are needed to reduce in-hospital
mortality in this population and attention has to be turned to the de-
velopment of systems addressing the continuum of STEMI care,
from symptom onset through return to community. To this regard,
an unmet need is to address the coronary microvascular functional
and structural obstruction (CMVO), which occurs frequently even
after prompt epicardial recanalization of the infarct-related artery.
Coronary microvascular dysfunction has been shown to increase
the risk of cardiovascular events regardless of the epicardial disease
status.5,6 Hence, at the time of reperfusion, patients with pre-
existent microvascular dysfunction will benefit less from prompt
reopening of the epicardial vessel, thus underscoring that, preserv-
ing a normal microvascular function before acute coronary occlu-
sion, is a crucial target of preventive therapies for CMVO similarly
to those aiming at restoring flow in the microcirculation during pri-
mary PCI and thereafter in the coronary care unit (CCU). In this art-
icle, we review mechanisms, diagnosis, and prognosis of CMVO in
acute STEMI, also addressing the prevention and treatment of
CMVO by highlighting the need for an integrated approach in differ-
ent time windows.
Mechanisms of coronary
microvascular dysfunction
and obstruction
Pre-existing coronary microvascular
dysfunction
Traditional and non-traditional risk factors play a role in epicardial
and microvascular endothelial-dependent dysfunction, specifically
in the high-risk subset with STEMI (Figure 1).5,7 Furthermore, previ-
ous studies indicate that abnormal non-endothelium-dependent
microvascular dilatation appears to be involved in functional and
structural alterations that lead to impaired coronary flow reserve
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(CFR) with aging, hypertension, diabetes, dyslipidaemia, insulin re-
sistance, and chronic inflammatory diseases.7
In one study among patients without obstructive coronary artery
disease (CAD), future cardiovascular events were limited to those
with a reduction of coronary blood flow in response to intracoron-
ary (IC) infusion of acetylcholine.8 Of note, endothelial dysfunction
represents an independent predictor of cardiovascular events.9 Ac-
cordingly, the presence of angina without evidence of angiographic
obstructive CAD is associated with the risk of cardiovascular events,
underscoring the potential role of coronary microvascular dysfunc-
tion in the pathogenesis of acute coronary syndrome (ACS).10
More specifically, a pre-existing impairment of the myocardial
microcirculation has been shown to yield greater vulnerability to
PCI-related myocardial injury as well as a poorer long-term out-
come.11,12 A pre-existing transient or permanent microvascular dys-
function may contribute to the development and prognosis of ACS
via reduction of coronary blood flow, leading to an alteration of
shear stress which aggravates endothelial dysfunction in epicardial
arteries and might enhance thrombus formation.5
Ischaemic injury
Four interacting mechanisms cause CMVO in humans: ischaemia-
related injury, reperfusion-related injury, distal embolization, and in-
dividual susceptibility of the microcirculation to injury (Figure 1).13,14
The first two mechanisms have been translated to humans from the
animal models with a first description by Kloner et al.15 Electron
Figure 1 There are four interacting mechanisms involved in the pathogenesis of coronary microvascular obstruction in humans:
ischaemia-related injury, reperfusion-related injury, distal embolization, and individual susceptibility (both genetic and due to pre-existing coornary
microvascular dysfunction) of the microcirculation to injury. Ischaemic injury: it depends on duration and extent of ischaemia and is characterized by
severe capillary damage, endothelial protrusions, and blebs that block the capillary lumen, and endothelial gaps with extra vascular erythrocytes (in
red). Interstitial myocardial oedema compresses capillaries and small arterioles, further decreasing flow through these dysfunctional vessels,
whereas sodium and calcium overload explains myocardial cell swelling. Reperfusion injury: the principal determinants of this phenomenon are
represented by neutrophils (in green), endothelin-1, thomboxane-A2, and platelets (in yellow). The obliteration of vessel lumen by neutrophil-
platelet aggregates is associated with release of vasoconstrictors and inflammatory mediators (in brown). Furthermore, in cardiomyocytes, reper-
fusion stimulates the production of reactive oxygen species by mitochondria further aggravating microvascular function. Finally, reperfusion may
increase infarct size due to mitochondria swelling and cell rupture based on opening of the mitochondrial membrane permeability transition, as
well as favour intra-myocardial haemorrhage.Distal embolization: distal embolization (in blue) of plaque and thrombus material may obstruct mech-
anically the microcirculation, but it is also a source of vasoconstrictors and procoagulant substances. Both thrombus and plaque features modulate
the effect of distal embolization on coronary microvascular obstruction. Individual susceptibility of the microcirculation to injury: Factors modulating
individual susceptibility to coronary microvascular obstruction are presented by genetic variability, diabetes, acute hyperglicaemia, hypercholes-
terolaemia, and lack of pre-conditioning.
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microscopic analysis after 90 min coronary occlusion followed by
reperfusion, revealed severe capillary damage, endothelial protru-
sions and blebs that appeared to block the capillary lumen, and
endothelial gaps with extra vascular erythrocytes.16 Due to the
loss of the glycocalix with expression of P selectin on endothelial
cells adhesion of inflammatory cells to the endothelium was com-
mon. Furthermore, interstitial myocardial oedema compresses ca-
pillaries and small arterioles, further decreasing flow through
these dysfunctional vessels.15 Sodium and initial calcium overload
explainsmyocardial cell swelling, associated tomild opening of mito-
chondrial membrane permeability transition pores. Importantly, in
this phase collateral circulation may protect from CMVO.
The most important clinical predictor of ischaemia-related injury
is ischaemia duration, but ischaemic extent also plays an important
role as confirmed by the association of electrocardiographic, echo-
cardiographic, and angiographic indices of myocardial ischaemia ex-
tent and prevalence of CMVO.17
Reperfusion injury
When ischaemia lasts .3 h, ischaemia-associated injury is poten-
tiated by reperfusion injury.18 In particular, lethal reperfusion injury
(myocardial necrosis due to reperfusion) and CMVO play a major
role. Coronary microvascular dysfunction and obstruction is caused
by further obliteration of vessel lumen by neutrophil-platelet aggre-
gates, which in turn produce large amount of vasoconstrictors and
inflammatory mediators.19 Furthermore, in cardiomyocytes, reper-
fusion stimulates the production of radical oxygen species by mito-
chondria that along with rapid normalization of pH lead to opening
of mitochondrial membrane permeability transition pores, calcium
overload, mitochondrial swelling, and cell disruption.19 Again, neu-
trophils, a major source of oxidants, proteolytic enzymes, and
pro-inflammatory mediators in hearts reperfused in vivo after pro-
longed ischaemia, may exacerbate CMVO in humans.19
Moreover, endothelial cells can modulate leucocyte function by
expression of adhesion molecules, e.g. intercellular adhesion
molecule-1 or P-selectin, and by release of soluble factors including
nitric oxide, prostacyclin, and endothelin.17 Finally, functional
changes during CMVO can be due to release of bioactive factors
from coronary plaque (e.g. endothelin-1, tissue factor, and micro-
particles) which have the potential to increase the severity of the
functional impairment of the coronary circulation. Interestingly,
one study found that IC infusion of tissue factor in a porcine model
caused CMVO.20 Moreover, oxidative stress and ischaemia per se
reduce the bioavailability of nitric oxide, further contributing to
the dysfunction of the myocardial microcirculation.17
Ischaemia followed by reperfusion may also favour intra-
myocardial haemorrhage (IMH). Indeed, hypoxia can disrupt the
endothelial barrier and damage the microvasculature and facilitate
blood cell extravasation upon reperfusion, thus causing IMH. It is
also possible that activation of inflammation and coagulation leads
to thrombosis, endothelial activation, and therefore consumption
of coagulation factors aggravating the haemorrhage.21
Specific cardiac magnetic resonance (CMR) sequences (T2-
weighted and T2*-weighted) identify iron in the tissue, thus showing
IMH in up to 40% of patients with CMVO. Of note, in an in vivo por-
cine model of reperfused STEMI, IMH at T2-weighted images and
at histology showed a close anatomical correlation.22
Importantly, patients with this more severe form of CMVO seem
to have a worse outcome than patients with CMVO but without
IMH.22
Distal embolization
A fourth important mechanism of CMVO is distal embolization.
Coronary micro-embolization in experimental models causes re-
gional contractile dysfunction due to release of tumour necrosis
factor-alpha. Of note, myocardial perfusion starts falling when mi-
crospheres obstruct.50% of coronary capillaries.23 Thus, the small
number of emboli during primary PCI in the setting of STEMI, al-
though not affecting myocardial perfusion may create a local react-
ing milieu with release of inflammatory and vasoactive substances
such as endothelin-1.23 Moreover, recent evidences demonstrated
that, in patients with STEMI, the coronary neutrophil extracellular
traps (NETs) burden correlates negatively with ST resolution
(STR) and positively with IS, thus suggesting that NETs may propa-
gate thrombosis and inflammation distally into the infarcted myocar-
dium and contribute to myocyte death during atheroembolism.24,25
Similarly, microparticles content of embolized material may worsen
reperfusion.26 These observations suggest that embolized material
is biologically active and that may aggravate reperfusion injury be-
yond its mechanical obstructive effect on the microcirculation.
Emboli of different size can originate from epicardial coronary
thrombus and from fissured atherosclerotic plaques during primary
PCI, but spontaneous embolization has been suspected also before
vessel manipulation. In some cases, an abnormal flow after PCI could
be due to the dislodgment of an obstructive thrombus distal to the
culprit lesion. Of note, this phenomenon is not detectable by angi-
ography thus requiring other methods of coronary imaging, like an-
gioscopy and optical coherence tomography (OCT).27,28 In this
context, as suggested by a recent OCT study, the persistence of
thrombus after stenting may lead to distal embolization even after
stent deployment.29 Interestingly, the effect of angiographically vis-
ible distal embolization on IS seems to be time-dependent.30 Both
plaque and thrombus features are associated to risk of distal embol-
ization. In particular, thrombus volume is associated with the occur-
rence of distal embolization, as well as the presence of a lipid rich
plaque.31 Furthermore, plaque erosion is more prone to distal em-
bolization when compared with plaque rupture in post-mortem
studies, and is more frequently associated to infarctlets, thus sug-
gesting that the thrombus type may play an important role. Hence,
major predictors of distal embolization are thrombus burden as as-
sessed by angiography or IC imaging, and plaque features as assessed
by OCT.
Individual susceptibility
A fifth pathogenetic component of CMVO is represented by individ-
ual susceptibility to microvascular dysfunction, maybe related to the
function, as well as to the structure and the density of the microcir-
culation.13 Genetic factors may modulate adenosine-induced vaso-
dilation. In particular, 1976T.C polymorphism of the adenosine 2A
receptors gene was suspected to be related with a higher preva-
lence of CMVO.32 Moreover, genetic variations within defined re-
gions of VEGFA and CDKN2B-AS1 genes have been showed to
be associated with coronary microvascular dysfunction, whereas
sex-specific allelic variants within MYH15, VEGFA, and NT5E genes
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seem to be related with an increased risk of coronary microvascular
dysfunction in men.33 Finally, patients with MVCO show a more
compact fibrin network, possibly suggesting a genetic-mediated re-
sistance to lysis.34 Another factor modulating the individual suscep-
tibility to CMVO is the presence of ischaemic pre-conditioning
(IPC), which seems to protect both the myocardium and the coron-
ary microcirculation.13 Accordingly, pre-infarction angina might help
preventing CMVO, by inducing IPC. Importantly, beneficial effect of
pre-infarction angina may be blunted in humans due to risk factors
or drugs therapy affecting unfavourably IPC,35 while chronic nitrate
therapy seems to stimulate IPC.36
Diagnosis of coronary
microvascular dysfunction
and obstruction
Diagnostic indices may be classified as invasive (Figure 2A) or non-
invasive (Figure 2B) tools. Of note, the incidence of CMVO is
variable, ranging from 10% by using angiographic assessment of
thrombolysis in myocardial infarction (TIMI) flow to 60% by using
CMR or myocardial contrast echocardiography (MCE).37 Based
on a combination of angiographic and electrocardiographic indices,
a reasonable estimate of patients who get optimal myocardial reper-
fusion is 35%.13 Furthermore, due to its dynamic nature, in 50% of
cases CMVO is irreversible, while in the remaining 50% it is revers-
ible.38 Of note, the majority of the studies assessing the incidence
of CMVO were performed in patients with STEMI. Indeed, only
few studies have assessed CMVO in patients with non-ST-segment
myocardial infarction (NSTEMI). In particular, these studies included
rather limited numbers of patients and their findings were contro-
versial.39,40 Recently, the largest study aimed at detecting the inci-
dence of CMVO in a cohort of NSTEMI reported a frequency of
13.8%, also establishing the localization of the culprit lesion and a
IS as independent predictors of CMVO.41
Invasive indices of coronary microvascular
dysfunction and obstruction
The gold standard method for assessing microvascular function is
the direct measurement of coronary blood flow velocity using an
ICDoppler wire. In this context, the other tools currently employed
to evaluate CMVO, such as ST elevation and biomarkers, may only
to be considered as surrogate markers. The typical flow pattern as-
sociated to CMVO is characterized by: systolic retrograde flow, di-
minished systolic anterograde flow, and rapid deceleration of
diastolic flow. The attenuated CFR response post-PCI is associated
with future cardiovascular events.42 However, the major obstacles
with this method are the need for special equipment and the use
of additional pharmacological interventions.
In this context, compared with CFR, the index of microvascular
resistance (IMR) provides a more reproducible assessment of
microcirculation, independent of haemodynamic parameters. More-
over, it has recently been shown to be a predictor of acute micro-
vascular damage and 3-month left ventricular functional recovery
after primary PCI.43 Again, the hyperaemic microvascular resistance
(HMR) index for Doppler-derived coronary flow has been shown to
be associated with ventricular recovery and clinical outcome after
STEMI.44 All together, these insights from clinical pathophysiology
could support therapeutic approaches beyond the primary PCI
procedure itself.
Thrombolysis in myocardial infarction score grading system
describes the rate of blood flow in the epicardial vessels, ranging
between no flow at all (Grade 0) to a normal flow rate (Grade 3);
TIMI flow ,3 is a marker of both CMVO and of larger IS and has
been shown to affect prognosis both at short and long-term follow-
up.45 However, CMVO may occur in nearly 50% of patients with
TIMI flow 3. Gibson et al. described the TIMI frame count (TFC) in-
dex as the number of frames required for contrast medium to reach
a standardized distal landmarks, that may stratify the prognosis of pa-
tients exhibiting TIMI flow 3 and correlate with invasive assessment
of CFR.46 In the next years, angiographic methods based on the ki-
netics of dye penetration within the myocardium (myocardial
‘blush’), the myocardial blush grade (MBG), and TIMI myocardial
perfusion grade (TMPG), have been developed in order to shift
the attention from the epicardial flow to the microcirculatory
flow by angiography.47,48 Myocardial blush grade is a densitometric
method assessing maximum intensity of contrast medium in the
microcirculation. More intensely, the myocardial blush and faster
its clearance, better the microvascular perfusion. Myocardial blush
grade is scored on a scale of 0–3, with higher scores indicating bet-
ter perfusion. The TMPG assesses microvascular clearance of con-
trast medium and is scored again on a scale of 0–3. Both MBG and
TMPG are able to risk stratify patients having final TIMI flow 3. Thus,
it is becoming common practice to define angiographic CMVO, as
follows: TIMI flow grade ,3 or 3 with an MBG or TMPG 0 to
1.37 Angiographic methods to assess perfusion (TIMI, TFC, and
MBG and TMPG) may have reproducibility concern outside core la-
boratory centres, thus invasive assessment of microcirculation dur-
ing primary PCI are emerging including IC pressure and flow wires
or their combination to detect the presence of CMVO.37 However,
no large studies have compared diagnostic accuracy of angiographic
vs. wires obtained indices of CMVO so far.
Non-invasive indices of coronary
microvascular dysfunction and
obstruction
After primary PCI, incomplete STR has been related to CMVO and
worse clinical outcome.49 Different methods have been focused on
the assessment of multiple leads or single leads showing maximum
ST elevation at baseline.49 Thus, a consensus is still lacking about
which leads to analyse, the optimal timing of electrocardiogram
(ECG) analysis, and whether standard ECG or continuous ECG
monitoring is preferable. Assessment of single lead STR showing
maximum ST elevation at baseline seems to be as accurate as the
sum STR measurements.50 Of note, residual ST-segment elevation
was found to be an independent marker of CMVO in a recent study
and approximately one-third of patients with TIMI flow Grade 3 and
MBG 2–3 do not exhibit STR.51 Angiography and ECG are obtained
at two different times after primary PCI and theymay reflect different
aspects of myocardial reperfusion, with angiography looking more at
the coronary microcirculation and ECG more at myocardial cells.13
Myocardial contrast echocardiography utilizes ultrasound to visu-
alize contrast microbubbles with a rheology similar to that of red
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blood cells that freely flow within patent microcirculation while lack
of intra-myocardial contrast opacification is due to microvascular
obstruction that predicts functional recovery after STEMI.52 Myo-
cardial contrast echocardiography exhibits several limitations: mod-
erate spatial resolution, operator dependency, and incomplete left
ventricular coverage with suboptimal visualization of the lateral
wall, and semi-quantitative assessment of CMVO.
Cardiac magnetic resonance allows multislice imaging with high
tissue contrast and high spatial resolution, enabling accurate quanti-
fication and localization of CMVO and IS relative to the entire left
ventricle. Cardiac magnetic resonance-defined CMVO correlates
with MCE, angiographic, and invasive indices used for the assess-
ment of CMVO.53 In particular, it can be diagnosed as: (i) lack of
gadolinium enhancement during first pass (,2 min) and (ii) lack of
gadolinium enhancement within a necrotic region, identified by late
gadolinium hyper-enhancement (after 10–15 min). First pass (early)
CMVO is more sensitive than late CMVO, as the latter underesti-
mates the extent of CMVO. Cardiac magnetic resonance may give
additional hints to the presence of IMH that appears to be conse-
quence of microvascular injury in humans.21,22 Indeed, a clinical
study using CMR imaging for detection of IMH and MCE for detec-
tion of perfusion defects, demonstrated that IMH occurred in
Figure 2 The diagnostic indices for coronary microvascular obstruction detection, classified as invasive (green circle) (A) or non-invasive tools
(blue circle) (B). Invasive indices: The gold standard method for coronary microvascular dysfunction and obstruction assessment is the direct
measurement of coronary flow reserve using intracoronary Doppler wire; the typical coronary microvascular dysfunction and obstruction pattern
is characterized by systolic retrograde flow, diminished systolic anterograde flow, and rapid deceleration of diastolic flow. The figure at the bottom,
left position, shows the systolic retrograde flow (white arrows) during intracoronary Doppler. The index of microvascular resistance provides a
more reproducible assessment of microcirculation, independent of haemodynamic pertubations whereas hyperaemic microvascular resistance is
associated with ventricular recovery and clinical outcome after ST-segment elevation myocardial infarction. The image at the bottom, right pos-
ition, shows the typical pattern of coronary microvascular dysfunction and obstruction: reduced coronary flow reserve and increased index of
microvascular resistance/hyperaemic microvascular resistance. Angiographic parameters of coronary microvascular dysfunction and obstruction
are represented by thrombolysis in myocardial infarction flow score, myocardial blush grade, and thrombolysis in myocardial infarctionmyocardial
perfusion grade. Of note, it is becoming common practice to define angiographic coronary microvascular dysfunction and obstruction as follows:
thrombolysis in myocardial infarction flow grade ,3 or 3 with an myocardial blush grade or thrombolysis in myocardial infarction myocardial
perfusion grade 0–1. The image at the top shows a case of angiographic coronary microvascular dysfunction and obstruction (white arrow) in
the posterior descending artery of the right coronary artery. Non-invasive indices (light blue circle): ST-segment resolution represents an useful tool
of coronary microvascular dysfunction and obstruction, also considering its prognostic value (see the image at the top, left position, for the ST
before opening infarct-related artery; see the image at the top, right position, for the ST after opening infarct-related artery during coronary micro-
vascular dysfunction and obstruction). Myocardial contrast echocardiography can be employed for coronary microvascular dysfunction and ob-
struction diagnosis. The typical pattern is represented by lack of intra-myocardial contrast opacification (indicated by white arrows, in the image in
the centre, left position). Cardiac magnetic resonance allows multislice imaging with high tissue contrast and high spatial resolution, enabling ac-
curate quantification, and localization of coronary microvascular dysfunction and obstruction and infarct size relative to the entire left ventricle;
typical signs of coronarymicrovascular dysfunction and obstruction are represented by lack of gadolinium enhancement during first pass (indicated
by white arrow, in the image at the bottom, on the left position) and lack of gadolinium enhancement within a necrotic region (late gadolinium
hyper-enhancement) (indicated by white arrow, in the image at the bottom, on the right position). Finally, the hybrid positron emission tomog-
raphy/cardiac computed tomography allows to monitor inflammatory reactions after reperfusion (indicated by white arrows, within the image in
the centre, on the right position).
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patients with sizable contrast defects only.54 Other imaging tech-
niques have been utilized or are under investigation for CMVO de-
tection including myocardial scintigraphy or hybrid positron
emission tomography-computed tomography, with promising re-
sults as they may allow to monitor inflammatory reactions after
reperfusion.55
Prognosis of coronary
microvascular dysfunction
and obstruction
Indices of CMVO predict adverse left ventricular remodelling and
mortality after primary PCI (Figure 3; Supplementary material online,
Table S1). In particular, TIMI flow ≤2 is associated with an
increased risk of adverse remodelling at 6 months58 and of 5-year
mortality.59 Myocardial blush grade 0–1 increases the risk of
adverse remodelling at 6 months60 and of total mortality after
16 months of follow-up.61 Myocardial contrast echocardiography
detected CMVO increases the risk of adverse remodelling at
6 months52 and of cardiac death after 46 months.57 Cardiac magnetic
resonance detected CMVO increases the risk of adverse remodel-
ling at 6months62 and of death.63 The lack of STR increase the risk of
total mortality after 30 days but failed to consistently predict ad-
verse left ventricular remodelling.58 The combination of poor
MBG (0 to 1) and lack of STR showed an additive effect on the
risk of total mortality after 1 year, thus suggesting that angiographic
and ECG indices of CMVO may reflect different pathogenetic me-
chanisms.56 Finally, CMR markers of myocardial damage (IS and es-
pecially CMVO) provided independent and incremental prognostic
Figure 3 The prognostic role of coronary microvascular obstruction: at the top left, Kaplan–Meier survival curve showing, at long-term follow-
up (100 months), that patients in the coronary microvascular obstruction group, evaluated by angiographic thrombolysis in myocardial infarction
flow, had a significantly higher incidence of cardiac death (%), compared with those without coronary microvascular obstruction (log-rank
P, 0.0001).45 At the top right, Kaplan–Meier survival curve showing cumulative adverse event rates (%), according to myocardial blush grade,
among patients with and without ST-segment resolution, during 1 year follow-up (log-rank P ¼ 0.01). In particular, among patients with ST-seg-
ment resolution, 70%, the cumulative adverse event rate was 10.1% for myocardial blush grade 0/1, and 6.3% for myocardial blush grade 2/3.
Among patients with ST-segment resolution . 70%, the cumulative event rate was 5.1% for myocardial blush grade 0/1, and 1.2% for myocardial
blush grade 2/3.56 At the bottom left, Kaplan–Meier survival curve showing combined event free survival (%) in patients with and without micro-
vascular reperfusion, after perfused acute myocardial infarction, evaluated by myocardial contrast echocardiography. In particular, patients with-
out microvascular reperfusion exhibit a higher cumulative 5-year combined event rate (long-rank test P, 0.0001), than those without
microvascular dysfunction.57 At the bottom right, Kaplan–Meier survival curve showing combined event free survival (%) in patients with and
without microvascular obstruction, after perfused acute myocardial infarction, evaluated by magnetic resonance imaging. In particular, patients
with microvascular obstruction exhibit a higher cumulative 2-year combined event rate (long-rank test P ¼ 0.001) than those without microvascu-
lar obstruction.22
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information in addition to clinical risk score and left ventricular ejec-
tion fraction (LVEF) in a recent large study in patients with STEMI.64
Treatment strategies in different
time windows
During the years, many efforts have been made in order to detect an
effective strategy to prevent and approach CMVO. In this context,
management of CMVO should follow the same time windows of
treatment commonly utilized for STEMI patients (Figure 4). Three
phases may thus be identified. The first time window is broad and
extends until hospital admission for STEMI. The second time win-
dow is in catheterization laboratory which provides the unique op-
portunity to target directly the coronary microcirculation supplied
by the infarct-related artery. The third time window is, after cath-
eterization laboratory, in the coronary care unit where both mech-
anical and pharmacological interventions may be implemented to
reverse CMVO.
It has to be highlighted that currently no treatment has convin-
cingly been proved to be beneficial for the prevention or treatment
of CMVO in a multicenter controlled randomized trial with clinical
endpoints. For this reason, in each time window, we have arbitrarily
divided therapies into three groups: (i) therapies with evidence
and/or general agreement of possible utility and that need to be
tested in large trials with clinical endpoints, (ii) therapies that still
need confirmation due to limited or conflicting evidence and/or di-
vergence of opinion about their utility (controversial therapies), and
(iii) therapies for which the general agreement is that they are
ineffective (inadequate therapies) (Supplementary material online,
Table S2, Figure 4).We hope that this approachmight provide a com-
prehensive framework for setting up a coordinated therapeutic
approach to the management of CMVO, which spans from preven-
tion to treatment.
Before the catheterization laboratory
Therapies to be tested in large trials with clinical endpoints
Ongoing statin therapy at the time of STEMI was associated to a low-
er rate of CMVO, and better functional recovery of myocardial func-
tion after 6 months of follow-up when compared with patients not
on statin.65 Recently, the administration of high doses of statins prior
to primary PCI has been found to improve CMVO when compared
with that of low doses.66
Regarding b-blockers, pre-clinical studies showed that the third-
generation b-blockers like carvedilol and nebivolol are able to
Figure 4 The current treatments of coronary microvascular dysfunction and obstruction in different time windows: before catheterization la-
boratory, in the catheterization laboratory, and after catheterization laboratory. In particular, the green circles show the therapies to be tested in
large trials with clinical endpoints, the green circles report the controversial therapies and the ochre circles show the inadequate treatments. ANP,
atrial natriuretic peptide; COX, cyclooxygenase; GIK, glucose–insulin–potassium; IABP, intra-aortic balloon pumping; IC, intracoronary; IPC, is-
chaemic post-conditioning; LDD, local drug delivery; RIC, remote ischaemic conditioning; RIPC, remote ischaemic pre-conditioning; rt-PA, recom-
binant tissue-type plasminogen activator; SOD, superoxide dismutase.
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protect microcirculation and reduce the IS.67,68 Of note, b-blockers
given early after chest pain onset may be of utility. Intravenous (IV)
metoprolol, administered in ambulance in patients with anterior
STEMI on Killip class II or less, has been shown to reduce IS, increase
LVEF, and reduce the need for implantable cardioverter-defibrillator
implantation, with fewer admissions due to heart failure after 2
years.69 Among antiplatelet drugs commonly used in STEMI pa-
tients, pre-hospital abciximab administration may be useful.70 Of
note, the FINESSE trial demonstrated that upstream administration
of abciximab with half-dose reteplase significantly reduces IS but
does not have any overall clinical benefit in primary study endpoint
at 90 days as well as in mortality at 1 year.71 On the other hand, the
On-TIME-2 trial showed as a routine pre-hospital initiation of high-
bolus dose tirofiban might improve STR and clinical outcome after
PCI.72
Conditioning strategies can be implemented after chest pain on-
set only. Accordingly, Botker et al. showed that, applying three 5-min
cycles of brief ischaemia and reperfusion of the upper arm by using
blood pressure cuff, myocardial salvage was increased in STEMI pa-
tients undergoing primary PCI, especially in thosewith a large area at
risk.73 Of note, adding morphine to remote ischaemic pre-
conditioning (RIPC) protocol further improved of STR.74 This
form of protection is called RIPC, as ischaemia of an organ may
lead to protection of a distant organ.
Controversial therapies
Results of studies with the glucose–insulin–potassium (GIK) in the
setting of STEMI have been controversial.75,76 The CREATE ECLA
provided indeed neutral results with no difference in 30 days mor-
tality with GIK when compared with placebo.75 Conversely, the re-
cent IMMEDIATE trial showed reduction in IS and lower rate of
in-hospital mortality and cardiac arrest in patients randomized
GIK than in controls, with trial treatment started in the ambulance
by paramedics suggesting to start treatments very early after chest
pain onset.76 Similarly, the role of chronic treatment and early
re-administration of ACE inhibitors or nitrates, both associated
with better reperfusion in small retrospective studies, should be
tested on a large scale.36,77
Finally, evidence from a new experimental study proposed a
therapeutic potential role of NET-targeted intervention in myocar-
dial injury-reperfusion injury and CMVO.78 Indeed, DNase I, which
targets NETs, in combination with recombinant tissue-type plas-
minogen activator (rt-PA), which targets fibrin, should be an ideal
option to disrupt the NET- and fibrin-provided mesh like backbone
structure of thrombus.
Inadequate therapies
Apart from IIb–IIIa inhibitors, new oral antiplatelet drugs have pro-
vided conflicting results. In particular, a sub-analysis of PLATO trial,
failed to find differences with regard to myocardial perfusion be-
tween clopidogrel and ticagrelor79 and in large ATLANTIC study,
pre-hospital administration of ticagrelor, in patients with acute STE-
MI, did not improve pre-PCI coronary reperfusion as assessed by
STR.80 Of note, among thienopyridines, ticagrelor only was tested
in large clinical trials in order to evaluate its effect on pre-PCI cor-
onary reperfusion. A small study using CMR to assess CMVO
showed that clopidogrel pre-treatment in STEMI may improve
reperfusion.81 Finally, no data are available regarding the efficacy
of prasugrel on CMVO.
ITF-1697, a C-reactive protein-derived tetrapeptide, was tested in
a multicentre randomized double-blind study. In particular, IV infu-
sion of four dosages of ITF-1697 or placebo was started before
PCI and continued for 24 h. Post-procedure perfusion, assessed by
TIMI flow, corrected TFC,MBG, and STRwas similar for the placebo.
Furthermore, the results showed no differences between the treat-
ment regimes in enzymatic IS or clinical outcome up to 30 days.82
On the other hand, starting from previous consistent evi-
dences,83,84 a new theoretical basis for the clinical application of
COX inhibitors in the prevention and treatment of CMVO has
been recently provided,85 although their thrombogenic action is
likely to be an insurmountable limitation.
Finally, in the CHILL-MI study, hypothermia induced by cold saline
and endovascular cooling failed to show a reduction of IS and
CMVO.86
In the catheterization laboratory
Therapies to be tested in large trials with clinical endpoints
Adenosine can prevent CMVO through several mechanisms. The
AMISTAD trial suggested that IV adenosine started before reperfu-
sion might improve the outcome when given early (,3.2 h from
chest pain onset) when compared with placebo.87,88 In the last
few years, other reports have provided mixed results regarding
the role of IC adenosine.89–93 Differences in way of administration,
timing and dosages may explain these discrepancies. In the
REOPEN-AMI trial, we found high dosages of IC adenosine, given
after thrombus aspiration through the aspiration catheter, improved
STR, and enzymatic IS when compared with placebo or sodium ni-
troprusside, which translated in a reduction of major adverse car-
diac events (MACEs) and a better left ventricular remodelling at
1-year follow-up.94,95
Atrial natriuretic peptide (ANP), cyclosporine, and exenatide,
known to have cardioprotective effects, have shown beneficial ef-
fects on IS while the effect on indices of CMVO is neutral or not re-
ported.96–98
In the J-Wind trial, ANP, which activates the RISK cardioprotec-
tive pathways, reduced enzymatic IS, and improved LVEF.96
Exenatide, a glucagon-like peptide-1 agonist, has been shown to
reduce IS when administered at time of reperfusion in animal mod-
els. Exenatide, started 15 min before primary PCI and given intra-
venously for 6 h post-procedure, increased salvage index but
30-day clinical events were similar when compared with placebo.98
Cardioprotection by mechanical remote conditioning may be
given during primary PCI. Indeed, a recent study showed that remote
conditioning (3 cycles of ischaemia/reperfusion of the lower limb) at
the time of primary PCI reduced enzymatic IS, and was associated
with an improvement of T2-weighted oedema volume assessed by
CMR and STR when compared with conventional primary PCI.99
Controversial therapies
Initial small single centre studies about thrombus aspiration showed
promising results with regard to functional or structural indices of
CMVO,100 whereas clinical efficacy was then confirmed in the larger
TAPAS101; indeed, at 1-year follow-up mortality was lower in pa-
tients randomized to manual thrombus aspiration than in those
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randomized to conventional primary PCI.102 Later, the TASTE trial
randomized 7244 patients with STEMI to manual thrombus aspir-
ation or to conventional primary PCI. Death from any cause after
30 days occurred in 2.8% and in 3.0% of patients, respectively.103
After 1 year, no mortality benefit was associated with manual
thrombus aspiration.104 Eventually, the TOTAL trial has recently
clarified as, in patients with STEMI undergoing primary PCI, routine
manual thrombectomy when compared with PCI alone did not re-
duce the risk of cardiovascular death, recurrent MI, cardiogenic
shock, or NYHA class IV heart failure within 180 days but was asso-
ciated with an increased rate of stroke within 30 days.105 On the
other hand, the Angiojet mechanical thrombectomy device in the
JETSTENT study, that included patients with acute MI and angio-
graphic evidence of large thrombus burden, showed improvement
in STR in the treatment group. Importantly, after 1 year, MACEs
rate were 14.9% in the Angiojet group vs. 22.7% in the direct stent-
ing group.106 Nevertheless, thrombus aspirationmay have some lim-
itations. In particular, one recent OCT study failed to show larger
lumen area after thrombus aspiration when compared with that
observed after conventional primary PCI.29 Thus, other approaches
including stent with trapping capabilities107 and local delivery of ab-
ciximab at culprit lesion level through special porous balloon108
failed to improve clinical outcome. Interestingly, in recent a study,
patients with STEMI and at least 1 risk factors for CMVO were ran-
domized to a strategy of immediate stenting vs. delayed stenting (the
vessel was initially recanalized by thrombus aspiration or minimal
balloon dilatation followed by IIb– IIIa infusion).109 The authors
showed lower rate of CMVO and greater myocardial salvage index
at 6 months in the deferred group, thus suggesting that leaving time
form residual thrombus dissolution before stenting may play an
important role in the prevention of CMVO.
Vasodilators may be given in the catheterization laboratory, includ-
ing verapamil, diltiazem, and nitroprusside.110,111 While all have been
associated with improvement of flow by angiography, clinical out-
come data are lacking for calcium-antagonists,110 or controversial
for nitroprusside.111
Inadequate therapies
Intracoronary administration of abciximab failed to improve MACEs
(all-cause mortality, recurrent MI, and new heart failure) and CMVO
rate at 3 months when compared with its IV administration.112 Simi-
larly, nicorandil, a hybrid drug of ATP-sensitive K-channel opener
and nicotinamide nitrate, in the large J-WIND trial failed to improve
clinical outcome.96
While RIPC given early before reperfusion is a promising therapy,
post-conditioning that refers to stuttering or interrupted reperfu-
sion with a series of brief coronary artery re-occlusion-reperfusion
cycles before full and final reperfusion, had disappointing re-
sults.113,114 Most but not all studies on post-conditioning have
shown a beneficial effect on IS and CMVO.113 However, the largest
study so far published which randomized 700 patients to post-
conditioning vs.. conventional primary PCI failed to show improve-
ment of STR and clinical outcome at 30 days follow-up.114 An
appropriately sized study on post-conditioning with clinical
endpoints and 3 years of follow-up is ongoing (DANAMI-3).
Opening of mitochondrial permeability transition pores has a
central role in reperfusion injury, leading to mitochondria swelling
and cell death. Thus, new area of investigation is focus on protecting
the mitochondria during STEMI. Of note, IV infusion of TRO40303,
an inhibitor of the mitochondrial permeability transition pores,
failed to reduce IS or improve LVEF in patients with STEMI rando-
mized vs. placebo in the MITOCARE study.115
The recent data emerged from EMBRACE study showed as Bend-
avia, another potential mitochondria-targeted peptide able to cross
cell membranes and reduce ischaemia-reperfusion injury in animal
models, did not reduce myocardial damage in STEMI patients.116
Drugs able to reduce lethal reperfusion injury have shown nega-
tive results. In particular, the APEX-AMI aimed at assessing the effi-
cacy of pexelizumab, a humanized monoclonal antibody that binds
the C5 component of complement, failed to improved 30-days mor-
tality as well as TIMI-3 flow rate when compared with placebo.117
On the other hand, the FIRE trial conducted to test the FX06, a pep-
tide derived from human fibrin, failed to reduce IS or CMVO as as-
sessed by CMR.118 Of note, FX06 is able to compete with E1
fragments of fibrin for binding to an endothelial specific molecule,
VEcadherin, thereby acting as an anti-inflammatory.
Finally, most of the studies on erythropoietin have shown no ef-
fect on IS,119 and supersaturated oxygen therapy showed contro-
versial results.120
After the catheterization laboratory
Therapies to be tested in large trials with clinical endpoints
The aggressive risk factors modifications, guidelines-based therapy,
and rehabilitation all were proven to have a significant impact on the
recurrence of ACS and re-hospitalization. This therapeutic ap-
proach may exert its effect at least in part by improving coronary
microvascular dysfunction. Furthermore, as shown above, some
drug infusions started in the catheterization laboratory may be con-
tinued in CCU. In particular, beneficial effects have been shown for
IV IIb– IIIa inhibitors,121 adenosine,88 ANP,96 and more recently ex-
enatide.98 The duration of IV infusion for such therapies in CCU
should be matter of future studies, as currently tested drugs have
been given for variable times from 3 to 12 h. More prolonged ther-
apies (up to 24 h) may possibly increase the rate of reversible
CMVO that has been described to occur spontaneously in nearly
half of patients after 1 month.122
Controversial therapies
The effect of stem cells on CMVO has provided mixed results.123–125
Indeed, improvement of CFR after cell therapy has not consistently
been shown in all trials,123 conversely in the presence of CMVO, the
improvement of LVEF associated to stem cell treatment seems to
be blunted.124 Finally, in a recent study, the addition of cilostazol
(for 1 month) to double antiplatelet therapy with aspirin and clopi-
dogrel in patients with angiographic CMVO improved the clinical
outcome after 1 year.126
The use of vasodilators (calcium-channel antagonist, dypirida-
mole) or metabolic drugs (ranolazine) at discharge needs future
research having as endpoint reversion of CMVO, improved remod-
elling, and clinical outcome.127,128 Finally, endothelin-1 may be an-
other promising therapeutic target of.129,130
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Inadequate therapies
Intra-aortic balloon pumping (IABP) is able to reduce myocardial
oxygen demand due to systolic left ventricular unloading and
increases myocardial perfusion.131,132 However, Maekawa et al.
failed to show an increase of mean diastolic flow velocity and
peak diastolic flow velocity in left anterior descending by IABP in
patients with angiographic CMVO.131 Moreover, IABP failed to
reduce IS in high-risk PCI.132
Conclusions
The role of the microcirculation in determining short- and long-
term outcome following ACS continues to emerge. In this context,
over the past decades many studies have focused on the potential
mechanisms by which reperfusion damage contributes to the micro-
vascular abnormalities. The current review highlights a novel aspects
of the complex role of coronary microcirculation in ACS and pro-
motes the notion that pre-existing coronary microvascular dysfunc-
tion may play a major role in determining CMVO and outcome of
reperfusion strategies following primary PCI. Future trials should
explore the effects of integrated treatments aimed at prevention
and treatment of coronary microvascular dysfunction in this setting.
Supplementary material
Supplementary material is available at European Heart Journal online.
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